Abstract Number: 1478 • 2013 ACR/ARHP Annual Meeting
The Prevalence Of Biological Monotherapy Among Rheumatoid Arthritis Patients In Denmark: Results From The Danish Nationwide Danbio Registry
Background/Purpose: It is estimated that between 10 and 30% of rheumatoid arthritis (RA) patients are methotrexate (MTX)-intolerant and discontinuation is common in clinical practice. For…Abstract Number: 1480 • 2013 ACR/ARHP Annual Meeting
Prevalance Of Rare Variants In Methotrexate Pathway Genes: Implications From The National Heart Lung Blood Institute (NHLBI) Exome Sequencing Project
Background/Purpose: Inter-individual variation to methotrexate (MTX) therapy in patients with rheumatoid arthritis (RA) is attributed at least in part to the presence of genetic variation…Abstract Number: 1479 • 2013 ACR/ARHP Annual Meeting
Relationship Between physicians’ Decision To Use Concomitant Glucocorticoid and Remission During Treatment With Tocilizumab In Patients With Background Of Limited Dose Of MTX
Background/Purpose: Now, predictive factors at baseline for the good outcome of treatment with biologics are very important not to waste time to treatment goal “remission”.…Abstract Number: 1481 • 2013 ACR/ARHP Annual Meeting
Negative Effect Of Glucocorticoids Persistence Therapy On Porosity In Rheumatoid Arthritis Patients Treated With TNFα Blockers
Background/Purpose: Rheumatoid arthritis is the most common joint inflammatory disease associated with an increased risk of bone fractures. The standard of therapeutic strategy is to…Abstract Number: 1482 • 2013 ACR/ARHP Annual Meeting
Survival Of Biological Treatment In Chronic Inflammatory Arthritis: A Preliminary Analysis Of 13 Years Of Follow Up In Clinical Practice
Background/Purpose: The wide use of biological therapies (BTs) has largely modified the therapeutic approach in Chronic Inflammatory Arthritis (CIA). These relatively new drugs have different…Abstract Number: 1483 • 2013 ACR/ARHP Annual Meeting
Physician and Patient Characteristics Associated With The Decision To Treat Rheumatoid Arthritis Patients With Biologic Monotherapy In Usual Care Settings
Background/Purpose: Approximately 30% of rheumatoid arthritis (RA) patients treated with a biologic, receive the biologic as monotherapy i.e. without concomitant oral disease modifying anti-rheumatic drugs…Abstract Number: 1484 • 2013 ACR/ARHP Annual Meeting
Treatment With The Glucagon-Like Peptide-1 Analogue Liraglutide Is Associated With Amelioration Of Disease Activity In a Prospective Cohort Study Of Patients With Inflammatory Arthritis
Background/Purpose: Glucagon-like peptide-1 (GLP-1) analogues such as liraglutide, which are used for the treatment of type 2 diabetes (T2DM), mimic the action of endogenous incretin…Abstract Number: 1485 • 2013 ACR/ARHP Annual Meeting
RNA Transcripts From Peripheral Blood Mononuclear Cells As Predictors Of Clinical Responsiveness In Rheumatoid Arthritis Subjects Treated With Abatacept
Background/Purpose: Biologics, including abatacept (CTLA4Ig), improve outcomes for many RA patients. However, approximately 40-50% of RA patients fail to respond to abatacept, and there are…Abstract Number: 1486 • 2013 ACR/ARHP Annual Meeting
High Resolution HLA Analysis In Primary and Secondary Sjögren’s Syndrome
Background/Purpose: The Class II HLA-DR and HLA-DQ alleles have been associated with primary Sjögren’s Syndrome (SS) susceptibility. The aim of this study was to explore…Abstract Number: 1488 • 2013 ACR/ARHP Annual Meeting
Gene Expression Profile According To Systemic Disease Activity In Primary Sjögren’s Syndrome: Results From The Assessment Of Systemic Signs and Evolution Of Primary Sjögren’s Syndrome (ASSESS) Cohort
Background/Purpose: In primary Sjögren’s syndrome (pSS), the pathogenesis of systemic complications remains unclear. Only few gene expression studies were performed and concerned a limited number…Abstract Number: 1489 • 2013 ACR/ARHP Annual Meeting
RNA-Sequencing Identifies Novel Differentially Expressed Coding and Non-Coding Transcripts In Sjögren’s Syndrome
Background/Purpose: Sjögren’s syndrome (SS) is a common, clinically heterogeneous autoimmune disease characterized by exocrine gland dysfunction that involves both innate and adaptive immune responses. SS…Abstract Number: 1490 • 2013 ACR/ARHP Annual Meeting
Comparative Study Of The Transcriptome Of Minor Salivary Gland Of Sjögren’s Syndrome Patients Versus Healthy Controls Based On RNA-Seq
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a complex autoimmune disease characterized by a progressive hypofunction of the salivary and lachrymal glands. In order to better…Abstract Number: 1491 • 2013 ACR/ARHP Annual Meeting
Discovery and Validation Of Novel Micrornas In Minor Salivary Glands Of Sjögren’s Syndrome Patients
Background/Purpose: Sjögren's syndrome is a complex autoimmune disease of the salivary gland with an unknown etiology, so a thorough characterization of the transcriptome would facilitate…Abstract Number: 1494 • 2013 ACR/ARHP Annual Meeting
Increased Expression Of Interleukin 33 In Sera and Salivary Gland From Patients With Sjögren Syndrome
Background/Purpose: Interleukin 33 (IL-33), a member of IL-1 superfamily, exerts pro-inflammatory effect by binding with ST2 expressed on many cell types. Recently, the association of…Abstract Number: 1495 • 2013 ACR/ARHP Annual Meeting
Lesional Intereukin-21 Expression Correlates With Functional Germinal Center Formation and T Follicular Helper Cell Infiltration In The Salivary Glands Of Sjogren’s Syndrome
Background/Purpose: IL-21 is a pro-inflammatory cytokine that plays a key role in the activation and differentiation of B cells. B cells infiltrate the salivary glands…
ACR Meeting Abstracts